Recursion Pharmaceuticals (Recursion Pharmaceuticals) Stock Based Compensation

: $53.50 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

Recursion Pharmaceuticals's Stock Based Compensation for the three months ended in Dec. 2023 was $16.09 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 was $53.50 Mil.

Recursion Pharmaceuticals Stock Based Compensation Historical Data

The historical data trend for Recursion Pharmaceuticals's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Recursion Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Stock Based Compensation

1.39

4.29

14.84

27.91

53.50

Recursion Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Stock Based Compensation	Get a 7-Day Free Trial												7.70	8.81	11.81	16.79	16.09

Recursion Pharmaceuticals Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $53.50 Mil.

Recursion Pharmaceuticals Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Recursion Pharmaceuticals's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

Recursion Pharmaceuticals (Recursion Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Recursion Pharmaceuticals Inc (NAS:RXRX) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

N/A

Address

41 S Rio Grande Street, Salt Lake City,, UT, USA, 84101

Website

https://www.recursion.com

Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.

Executives

Michael Secora	officer: Chief Financial Officer	C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Shafique Virani	officer: Chief Corp. Dev. Officer	C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Dean Y Li	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Blake Borgeson	director	C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Christopher Gibson	director, 10 percent owner, officer: Chief Executive Officer	C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Tina Marriott Larson	officer: President and COO	C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY UT 84101
Zavain Dar	director	C/O LUX CAPITAL MANAGEMENT, LLC, 1600 EL CAMINO REAL - SUITE 290, MENLO PARK CA 94025
Terry-ann Burrell	director	C/O BEAM THERAPEUTICS INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
David J Mauro	officer: Chief Medical Officer	36 TERRELL DRIVE, WASHINGTON CROSS PA 18977
Mubadala Investment Co Pjsc	10 percent owner	P.O. BOX 45005, ABU DHABI C0 00000
Peter Hebert	other: Former 10% Owner	C/O LUX VENTURES, 295 MADISON AVE, 24TH FLOOR, NEW YORK NY 10017
Lux Ventures Iv, L.p.	other: Former 10% Owner	295 MADISON AVENUE, 24TH FLOOR, NEW YORK NY 10017
Lux Venture Partners Iv, Llc	other: Former 10% Owner	920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010
Lux Co-invest Partners, Llc	other: Former 10% Owner	C/O LUX CAPITAL, 920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010
Lux Co-invest Opportunities, L.p.	other: Former 10% Owner	C/O LUX CAPITAL MANAGEMENT, 920 BROADWAY, 11TH FLOOR, NEW YORK NY 10010